Publications by authors named "Eva Brand"

Claim this Profile
I
Impact of migalastat on cerebral outcomes in fabry disease - results from the prospective observational FAMOUS trial.
Momoko Choudhury, Malte Lenders, Pauline Laufer, Max Masthoff, Sima Canaan-Kühl, Eva Brand

Neurol Res Pract· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Progress and Challenges in the Treatment of Fabry Disease.
Malte Lenders, Elise Raphaela Menke, Eva Brand

BioDrugs· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of ER stress and the unfolded protein response on Fabry disease.
Malte Lenders, Elisa Rudolph, Eva Brand

EBioMedicine· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of enzyme replacement therapy and migalastat on disease progression in females with fabry disease.
Malte Lenders, Albina Nowak, Markus Cybulla, Jessica Kaufeld, Anja Friederike Köhn, Eva Brand

Orphanet J Rare Dis· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Renal and multisystem effectiveness of 3.9 years of migalastat in a global real-world cohort: Results from the followME Fabry Pathfinders registry.
Derralynn A Hughes, Gere Sunder-Plassmann, Ana Jovanovic, Eva Brand, Michael L West

J Inherit Metab Dis· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Relevance of Neutralizing Antibodies for the Pharmacokinetics of Pegunigalsidase Alfa in Patients with Fabry Disease.
Malte Lenders, Elise Raphaela Menke, Michael Rudnicki, Markus Cybulla, Eva Brand

BioDrugs· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical management of female patients with Fabry disease based on expert consensus.
Eva Brand, Aleš Linhart, Patrick Deegan, Ruxandra Jurcut, Antonio Pisani

Orphanet J Rare Dis· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
[
[What is confirmed in the treatment of Fabry's disease?].
Malte Lenders, Eva Brand

Inn Med (Heidelb)· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of enzyme replacement therapy on clinical manifestations in females with Fabry disease.
Malte Lenders, Albina Nowak, Markus Cybulla, Jessica Kaufeld, Anja Friederike Köhn, Eva Brand

Orphanet J Rare Dis· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Biochemical Amenability in Fabry Patients Under Chaperone Therapy-How and When to Test?
Malte Lenders, Elise Raphaela Menke, Eva Brand

BioDrugs· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comment to: Head-to-head trial of pegunigalsidase alfa versus agalsidase beta in patients with Fabry disease and deteriorating renal function: results from the 2-year randomised phase III BALANCE study-determination of immunogenicity.
Malte Lenders, Eva Brand

J Med Genet· May 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Complement activation and cellular inflammation in Fabry disease patients despite enzyme replacement therapy.
Björn Laffer, Malte Lenders, Elvira Ehlers-Jeske, Karin Heidenreich, Eva Brand

Front Immunol· February 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Screening for health-related quality of life and its determinants in Fabry disease: A cross-sectional multicenter study.
Yaroslav Winter, Max Hilz, Felix Beuschlein, Takahiro Tsukimura, Erich Seifritz, Eva Brand

Mol Genet Metab· November 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of enzyme replacement therapy and migalastat on left atrial strain and cardiomyopathy in patients with Fabry disease.
Christian Pogoda, Stefan-Martin Brand, Thomas Duning, Antje Schmidt-Pogoda, Jürgen Sindermann, Eva Brand

Front Cardiovasc Med· November 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Characterization of pre-existing anti-PEG and anti-AGAL antibodies towards PRX-102 in patients with Fabry disease.
Malte Lenders, Lina Marleen Feidicker, Stefan-Martin Brand, Eva Brand

Front Immunol· October 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
An expert consensus on the recommendations for the use of biomarkers in Fabry disease.
Alessandro Burlina, Eva Brand, Derralynn Hughes, Ilkka Kantola, Johannes KrÓ“mer

Mol Genet Metab· June 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical outcomes among young patients with Fabry disease who initiated agalsidase beta treatment before 30 years of age: An analysis from the Fabry Registry.
Robert J Hopkin, Gustavo H Cabrera, John L Jefferies, Meng Yang, Elvira Ponce, Eva Brand

Mol Genet Metab· February 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Patient reported quality of life and medication adherence in Fabry disease patients treated with migalastat: A prospective, multicenter study.
Jonas Müntze, Kolja Lau, Markus Cybulla, Eva Brand, Tereza Cairns

Mol Genet Metab· February 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Assessment and impact of dose escalation on anti-drug antibodies in Fabry disease.
Malte Lenders, Eva Brand

Front Immunol· December 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pre-existing anti-drug antibodies in Fabry disease show less affinity for pegunigalsidase alfa.
Malte Lenders, Solvey Pollmann, Melina Terlinden, Eva Brand

Mol Ther Methods Clin Dev· September 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Treatment of Fabry Disease management with migalastat-outcome from a prospective 24 months observational multicenter study (FAMOUS).
Malte Lenders, Peter Nordbeck, Christine Kurschat, Maria Eveslage, Nesrin Karabul, Stefan-Martin Brand, Eva Brand

Eur Heart J Cardiovasc Pharmacother· May 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Endothelial Dysfunction in Fabry Disease Is Related to Glycocalyx Degradation.
Solvey Pollmann, David Scharnetzki, Dominique Manikowski, Malte Lenders, Eva Brand

Front Immunol· February 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Fabry disease - a multisystemic disease with gastrointestinal manifestations.
Malte Lenders, Eva Brand

Gut Microbes· February 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Mechanisms of Neutralizing Anti-drug Antibody Formation and Clinical Relevance on Therapeutic Efficacy of Enzyme Replacement Therapies in Fabry Disease.
Malte Lenders, Eva Brand

Drugs· November 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
Î
α-Galactosidase a Deficiency in Fabry Disease Leads to Extensive Dysregulated Cellular Signaling Pathways in Human Podocytes.
Ulrich Jehn, Samet Bayraktar, Solvey Pollmann, Veerle Van Marck, Thomas Weide, Eva Brand

Int J Mol Sci· October 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis